Moderna Awarded Tender for the Supply of Its mRNA COVID-19 Vaccine in the European Union
Moderna (NASDAQ:MRNA) has secured a tender for supplying its mRNA COVID-19 vaccine in the European Union, Norway, and North Macedonia. The agreement allows 17 participating countries to access Moderna's vaccine for up to four years.
The company will provide various vaccine formats, including pre-filled syringes, which are preferred by healthcare providers as they can reduce administration errors and save time, potentially improving vaccination campaign efficiency.
This announcement follows the European Commission's marketing authorization granted in September 2024 for Moderna's updated COVID-19 mRNA vaccine Spikevax, which targets the SARS-CoV-2 variant JN.1. The vaccine is authorized for individuals six months of age and older.
Moderna (NASDAQ:MRNA) ha ottenuto un appalto per la fornitura del suo vaccino mRNA contro il COVID-19 nell'Unione Europea, in Norvegia e in Macedonia del Nord. L'accordo consente a 17 paesi partecipanti di accedere al vaccino di Moderna per un periodo massimo di quattro anni.
L'azienda fornirà vari formati di vaccino, tra cui siringhe pre-riempite, che sono preferite dai fornitori di assistenza sanitaria poiché possono ridurre gli errori di somministrazione e risparmiare tempo, migliorando potenzialmente l'efficienza delle campagne vaccinali.
Questo annuncio segue l'autorizzazione all'immissione in commercio concessa dalla Commissione Europea nel settembre 2024 per il vaccino mRNA aggiornato di Moderna, Spikevax, che mira alla variante SARS-CoV-2 JN.1. Il vaccino è autorizzato per individui di sei mesi di età e oltre.
Moderna (NASDAQ:MRNA) ha asegurado una licitación para el suministro de su vacuna mRNA contra el COVID-19 en la Unión Europea, Noruega y Macedonia del Norte. El acuerdo permite que 17 países participantes tengan acceso a la vacuna de Moderna por hasta cuatro años.
La compañía proporcionará varios formatos de vacuna, incluidos jeringas precargadas, que son preferidas por los proveedores de salud ya que pueden reducir los errores de administración y ahorrar tiempo, mejorando potencialmente la eficiencia de las campañas de vacunación.
Este anuncio sigue a la autorización de comercialización otorgada por la Comisión Europea en septiembre de 2024 para la vacuna mRNA actualizada de Moderna, Spikevax, que se dirige a la variante SARS-CoV-2 JN.1. La vacuna está autorizada para individuos de seis meses de edad en adelante.
모더나 (NASDAQ:MRNA)는 유럽 연합, 노르웨이 및 북마케도니아에 mRNA COVID-19 백신을 공급하기 위한 입찰에 성공했습니다. 이 계약은 17개 참여국이 모더나의 백신에 4년 동안 접근할 수 있도록 허용합니다.
회사는 의료 제공자들이 관리 오류를 줄이고 시간을 절약할 수 있어 예방접종 캠페인의 효율성을 개선할 수 있는 프리필드 주사기를 포함한 다양한 백신 형식을 제공합니다.
이번 발표는 모더나의 업데이트된 COVID-19 mRNA 백신인 Spikevax에 대한 유럽연합 집행위원회의 판매 허가가 2024년 9월에 부여된 이후 나오게 되었습니다. 이 백신은 6개월 이상의 개인에게 승인이납니다.
Moderna (NASDAQ:MRNA) a remporté un appel d'offres pour la fourniture de son vaccin COVID-19 à base d'ARNm dans l'Union européenne, en Norvège et en Macédoine du Nord. Cet accord permet à 17 pays participants d'accéder au vaccin de Moderna pendant quatre ans.
La société fournira divers formats de vaccin, y compris des seringues préremplies, qui sont préférées par les prestataires de soins de santé car elles peuvent réduire les erreurs d’administration et faire gagner du temps, améliorant ainsi potentiellement l'efficacité des campagnes de vaccination.
Cette annonce fait suite à l'autorisation de mise sur le marché accordée par la Commission européenne en septembre 2024 pour le vaccin mRNA COVID-19 mis à jour de Moderna, Spikevax, qui vise la variante SARS-CoV-2 JN.1. Le vaccin est autorisé pour les individus âgés de six mois et plus.
Moderna (NASDAQ:MRNA) hat einen Auftrag für die Lieferung seines mRNA COVID-19 Impfstoffes in der Europäischen Union, Norwegen und Nordmazedonien gesichert. Die Vereinbarung ermöglicht es 17 teilnehmenden Ländern, bis zu vier Jahre lang auf den Impfstoff von Moderna zuzugreifen.
Das Unternehmen wird verschiedene Impfstoffformate bereitstellen, darunter gewählte Fertigspritzen, die von Gesundheitsdienstleistern bevorzugt werden, da sie Verabreichungsfehler reduzieren und Zeit sparen können, was möglicherweise die Effizienz der Impfkampagnen verbessert.
Diese Ankündigung folgt der Marktzulassung, die der Europäischen Kommission im September 2024 für Modernas aktualisierten COVID-19 mRNA Impfstoff Spikevax erteilt wurde, der auf die SARS-CoV-2 Variante JN.1 abzielt. Der Impfstoff ist für Personen ab sechs Monaten zugelassen.
- Secured multi-year vaccine supply agreement with 17 European countries
- Opportunity for long-term revenue stream through four-year contract
- Recent EC approval for updated JN.1 variant vaccine formulation
- None.
Insights
The EU tender award marks a strategic victory for Moderna in maintaining its European market position amid evolving COVID-19 dynamics. The four-year agreement structure provides essential revenue visibility in a market that's transitioning from emergency response to endemic management.
The tender's significance extends beyond mere supply continuity. The inclusion of pre-filled syringe formats addresses a critical healthcare delivery efficiency gap, potentially reducing administration costs by
The timing of this agreement is particularly strategic, coinciding with the authorization of Moderna's JN.1 variant-specific formulation. This alignment positions Moderna to capture market share as healthcare systems adapt to emerging variants. The multi-country participation also suggests strong confidence in Moderna's mRNA platform and manufacturing capabilities.
From a business perspective, this agreement represents a vital shift in Moderna's commercial strategy from high-volume emergency contracts to more sustainable, long-term supply arrangements. This evolution is important for maintaining steady revenue streams as the COVID-19 market matures and becomes more competitive.
The Agreement provides participating countries with the opportunity to diversify their mRNA COVID-19 vaccine supply and gain access to pre-filled syringe vaccine formats
CAMBRIDGE, MA / ACCESS Newswire / January 24, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that it has been awarded a tender for the supply of its mRNA COVID-19 vaccine in the European Union (EU), Norway and North Macedonia. Under the resulting agreement, 17 participating countries can access Moderna's mRNA COVID-19 vaccine for up to four years.
"This agreement presents an opportunity for Moderna to support and strengthen national COVID-19 vaccination campaigns across participating countries," said Chantal Friebertshäuser, Senior Vice President, General Manager - Europe & Middle-East, Moderna. "Diversity of supply and availability of vaccine formats such as pre-filled syringes are vital to help increase vaccination rates and enhance vaccination campaign efficiency, ultimately strengthening health security."
Under the agreement, Moderna can provide its COVID-19 vaccine in several formats, including prefilled syringes. This is the preferred product presentation for healthcare providers as it can decrease the risk of administration errors and save time, which may ultimately improve vaccination campaign efficiency.
In September 2024, the European Commission (EC) granted marketing authorization for an updated formulation of Moderna's COVID-19 mRNA vaccine Spikevax, targeting the SARS-CoV-2 variant JN.1, for active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals six months of age and older.
About Moderna
Moderna is a leader in the creation of the field of mRNA medicine. Through the advancement of mRNA technology, Moderna is reimagining how medicines are made and transforming how we treat and prevent disease for everyone. By working at the intersection of science, technology and health for more than a decade, the company has developed medicines at unprecedented speed and efficiency, including one of the earliest and most effective COVID-19 vaccines.
Moderna's mRNA platform has enabled the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases. With a unique culture and a global team driven by the Moderna values and mindsets to responsibly change the future of human health, Moderna strives to deliver the greatest possible impact to people through mRNA medicines. For more information about Moderna, please visit modernatx.com and connect with us on X (formerly Twitter), Facebook, Instagram, YouTube and LinkedIn.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding: Moderna securing an agreement in the European Union for the supply of its mRNA COVID-19 vaccine; the opportunity and potential for up to 17 participating countries to order COVID-19 vaccines from Moderna over a four-year period; and healthcare provider preferences for prefilled syringes. The forward-looking statements in this press release are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond Moderna's control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements. These risks, uncertainties, and other factors include, among others, those risks and uncertainties described under the heading "Risk Factors" in Moderna's Annual Report on Form 10-K for the fiscal year ended December 31, 2023 and in subsequent filings made by Moderna with the U.S. Securities and Exchange Commission, which are available on the SEC's website at www.sec.gov. Except as required by law, Moderna disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release in the event of new information, future developments or otherwise. These forward-looking statements are based on Moderna's current expectations and speak only as of the date of this press release.
Moderna Contacts
Media:
Luke Mircea-Willats
Sr. Director, International Communications
Luke.mirceawillats@modernatx.com
Investors:
Lavina Talukdar
Senior Vice President & Head of Investor Relations
+1 617-209-5834
Lavina.Talukdar@modernatx.com
SOURCE: Moderna, Inc.
View the original press release on ACCESS Newswire
FAQ
How long is Moderna's (MRNA) new European vaccine supply agreement valid?
How many countries are included in Moderna's (MRNA) new European vaccine tender?
What new vaccine format is Moderna (MRNA) offering in the European tender?
When did the EC approve Moderna's (MRNA) updated JN.1 variant vaccine?
What age groups are eligible for Moderna's (MRNA) updated Spikevax vaccine in Europe?
